SELECT follow-up study to evaluate Long-term Impact oF anti-obEsity medication(EX9536-4750)

SELECT follow-up study to evaluate Long-term Impact oF anti-obEsity medication(EX9536-4750) - SELECT-LIFE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230250

Enrollment

110

Registered

2023-07-21

Start date

2023-09-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subjects with established CV disease and overweight or obesity

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Randomized into the SELECT clinical trial (EX9536-4388) and has not withdrawn consent, regardless of level of participation, dose achieved or treatment discontinuation. 2. Signed SELECT-LIFE consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

Exclusion criteria

Exclusion criteria: Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Design outcomes

Primary

Measure	Time frame
Death, Myocardial infarction, Stroke, Type 2 diabetes diagnosis, Concomitant medication, Body weight, Cancer and its location, Treatment for overweight or obesity, Surgery for knee replacement, Hospitalisation, Quality of life (EQ-5D-5L), Sleep apnoea	—

Countries

Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Romania

Contacts

Public ContactTakumi Okada

Novo Nordisk Pharma Ltd.

jphc_clinical_trials@novonordisk.com+81-362661000

Outcome results